focus -WSS

focus

author：hotspot 2025-09-29 01:09:15 - browse：6

Cheryl Meier had watched clinical trial enrollment announcements for years — but always for her sons’ type 1 diabetes, never for herself. Her OB-GYN had put her on Effexor for her depression 20 years ago, and it worked well enough — she could sleep for the first time in her life, and she no longer cried at every little thing. But it never worked for her dark thoughts.

But then she retired, and then she had time, and then she saw an email — “I guess once your name gets on a list, it’s there,” she said — for an experimental depression drug called zuranolone.

Unlike today’s crowded market of SSRIs, prescribed once and taken for months, years, or even indefinitely, zuranolone, developed by Sage Therapeutics, promises something different.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： FDA approves Moderna’s RSV vaccine, its second licensed product

hotspot

WSS

Senators push IRS to launch nonprofit hospital probe

Treatments for cramps don't cut it. Why aren't there better options?

Illumina board agrees to spin off Grail, as divestment plans proceed

Mark Cuban is blaming the wrong people for high drug costs

Senators tussle over abortion against the backdrop of a presidential campaign

Montana youths win climate lawsuit against state for promoting fossil fuels

leisure time

focus

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Eli Lilly’s Zepbound improved liver scarring in mid

What does generative AI mean for health care? We asked experts

Mark Cuban is blaming the wrong people for high drug costs

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Biden administration begins canceling student loan debt for 804,000 borrowers

Novavax promises a turnaround & Lilly roils the obesity market

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Hepatitis C has a cure — but many Americans still lack access to it

Indictment alleges Trump's ex

hotspot

BD to buy Edwards patient monitoring unit for $4.2 billion

An outdated Medicare rule harms dementia patients with anxiety

Sutter Health’s antitrust win overturned by appeals court

Novo Nordisk touts Wegovy study, but still struggling with supply

BMS, looking to build heart drug business, turns to AI for diagnosis

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

hotspot

hotspot

explore

explore